With $3.5 to $10 billion spent annually accounting for surgical site infections (SSI’s), many patients are still at least 2-11 times higher risk to die compared to non-infected in-patients. Certain procedures such as hip and knee replacement, cesarean, dental surgeries are prone to high SSI rates because current therapies are not optimally designed to reach the site of infection or might require revision surgeries.Chito-Armor is developed to deliver antibiotics at target site and prevent infection at surgery site
Early 2019, out team started to get together with great advisory support. Our team went through an 8-week extensive entrepreneur training with Mid-South Life Science TN’s Scipreneur Challenge in Memphis, TN. Later, the team participated in Fast-Pitch competition held by Crews center of Entrepreneurship at University of Memphis and won 1st place. In future, we see our company to evolve as a business entity and raise funds for a start-up.
Successful results from pre-clinical studies lead us to create an invention disclosure with the office of tech transfer at University of Memphis. Currently, we are in-progress with second stage of preclinical studies.
Chito-Armor team’s vision is to effectively fend off the post-surgical infections, reduce the hospital stay and comorbidity due to SSI in all types of surgeries. In case of hip and knee replacement surgeries, we want to prevent revision surgeries and in complications such as diabetes, control the spread of infections.